Table 2.

Molecular analysis of re-biopsy samples of evaluable patients

	Mechanisms of Resistance
Patient #	ALK FISH	ALK FISH CNG	ALK kinase domain sequencea	EGFR	KRAS
4	Positive	Negative	L1196M	WTa	WTa
5	Positive	Negative	L1196M	WTa	WTa
6	Positive	Negative	G1269A*	WTa,b	WTa,b
7	Positive	Positive	G1269A	WTb	WTb
8	Positive	Positive	WT	WTa	WTa
9a	Negative	Negative	NA	L858R a,b	WTa,b
9b	Positive	Negative	WT*	WTb	WTb
10¶	Positive/Negative§	Negative	WT	ND	G12C§b
11	Positive	Negative	WT	WTa	G12Va
12	Negative	Negative	WT	WTb	WTb
13¶	Positive	Negative	WT*	ND	ND
14	Positive	Negative	WT	WTa	WTa

^¶Patients with intrinsic resistance

^aDirect sequencing

^bSNaPshot® includes APC, AKT1, BRAF, CTNNB1, EGFR, FLT3, JAK2, KIT, KRAS, MAP2K1 (MEK1), NOTCH1, NRAS, PIK3CA, PTEN, TP53

^*Heterozygous for rs3795850 ALK SNP

^§From patient-derived cell line with loss of ALK gene rearrangement by FISH or RT-PCR .The FFPE tissue was ALK FISH +.